针对近日媒体出现的有关白蛋白使用的安全信息和不利事件报道,美国食品药品管理局(FDA)建议修订1998年以来倍受关注的白蛋白使用安全性指南。FDA现已将这些早先提出的安全性问题提上议事日程。这一决定与2005年3月美国血制品顾问委员会(BPAC)的建议相吻合,并就有关危重病人使用白蛋白问题提醒医疗专业人士,该问题曾在1998年被《英国医学杂志》报道,文中就使用白蛋白治疗危重患者的利弊进行了综合分析。 In response to recent media reports of safety information and adverse events related to albumin use, the FDA proposed to revise the guidelines on the safety of albumin used since 1998. The FDA has put these previously proposed security issues on the agenda. This decision, in line with the BPAC recommendation of March 2005 and reminding medical professionals on the use of albumin in critically ill patients, was reported by the British Medical Journal in 1998, A comprehensive analysis of the pros and cons of using albumin to treat critically ill patients was conducted.